Pioneering the next generation of pulmonary medicine and microbiome science

Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation. Alveolus Bio is focused on harnessing the therapeutic power of commensal bacteria strains and their byproducts for inhaled delivery straight to the target tissue: the lungs.

Origin Story

Alveolus Bio began in Dr. Vivek Lal’s Pulmonary Microbiome Lab and Dr. Amit Gaggar’s Program in Lung Protease and Matrix Biology at the University of Alabama at Birmingham (UAB).

The collaborating scientists published groundbreaking research on the neonatal lung microbiome, and became one of the first to conduct gain and loss of function studies on underlying mechanisms of neutrophilic inflammation and the extracellular matrix of the lung.

Research Infrastructure

At the heart of Alveolus Bio is world class infrastructure and personnel to support preclinical drug development for various respiratory diseases.

Alveolus Bio serves as a platform for respiratory drug development from discovery to clinical trials.